Table 2.
Univariate analysis of correlates of genomic testing interest, daily aspirin use, and receptivity to taking ASA/NSAID for cancer risk among CRC survivors (n = 273)
| Interest in Genomic Testing | Current ASA Use | Receptivity to ASA or NSAID Use1 | ||||
|---|---|---|---|---|---|---|
| Demographics | OR (CI 95%) | P-Value | OR (CI 95%) | P Value | OR (CI 95%) | P Value |
| Age | 0.98 (0.94–1.02) | 0.35 | 1.06 (1.02–1.10) | .006 | 0.96 (0.90–1.02) | 0.14 |
| Sex | ||||||
| Male | Ref | 0.32 | Ref | 0.86 | Ref | 0.24 |
| Female | 1.16 (0.61–2.19) | 0.95 (0.55–1.65) | 1.72 (0.70–4.24) | |||
| Residence | ||||||
| Urban | Ref | 0.41 | Ref | 0.13 | Ref | 0.88 |
| Rural | 0.76 (0.40–1.45 | 0.64 (0.36–1.14) | 1.08 (0.43–2.72) | |||
| Race | ||||||
| Ethnicity | ||||||
| Hispanic | Ref | 0.71 | Ref | 0.98 | Ref | 0.71 |
| Non-Hispanic | 1.13 (0.59–2.16) | 0.99 (0.57–1.73) | 0.84 (0.34–2.07) | |||
| Marital Status | ||||||
| Coupled | Ref | 0.02 | Ref | 0.94 | Ref | 0.69 |
| Uncoupled | 2.56 (1.18–5.55) | 0.98 (0.55–1.73) | 1.21 (0.47–3.17) | |||
| Education | ||||||
| ≤ High school or GED | 0.57 (0.29–1.12 | 0.84 (0.45–1.58) | 0.92 (0.35–2.42) | |||
| Beyond High School | Ref | 0.10 | Ref | 0.59 | Ref | 0.87 |
| Income | ||||||
| Low | Ref | 0.08 | Ref | 0.45 | Ref | 0.57 |
| Moderate–High | 1.85(0.93–3.66) | 1.26 (0.69–2.31) | 1.31 (0.52–3.34) | |||
| Time since Dx | ||||||
| ≤ 5 years | Ref | 0.33 | Ref | 0.99 | Ref | 0.17 |
| > 5 years | 1.37 (0.73–2.59 | 1.00 (0.58–1.73) | 0.53 (0.21–1.32) | |||
| Cancer Stage | ||||||
| Stage I-II | Ref | 0.57 | Ref | 0.77 | Ref | 0.64 |
| Stage III | 0.83 (0.43–1.60) | 0.92 (0.51–1.64) | 1.26 (0.48–3.28) | |||
| CRC in 1st degree relative | ||||||
| Yes | 1.09 (0.43–2.79) | 1.91 (0.93–3.94) | 0.51 (0.15–1.74) | |||
| No | Ref | 0.85 | Ref | 0.08 | Ref | 0.28 |
| Recurrent CRC | ||||||
| Yes | 0.94 (0.26–3.42) | 1.67 (0.59–4.70) | 0.68 (0.13–3.50) | |||
| No | Ref | 0.93 | Ref | 0.33 | Ref | 0.65 |
| Health related Factors | ||||||
| Health literacy | ||||||
| Low | 0.39 (0.11–1.37) | 1.03 (0.35–3.02) | 0.43 (0.10–1.90) | |||
| Medium | 0.23 (0.11–0.48) | 1.67 (0.94–2.97) | 0.96 (0.38–2.47) | |||
| High | Ref | 0.0006 | Ref | 0.14 | Ref | 0.53 |
| General health | ||||||
| Positive | Ref | 0.98 | Ref | 0.95 | Ref | 0.94 |
| Negative | 1.01 (0.49–2.07) | 1.02 (0.55–1.90) | 0.96 (0.33–2.83) | |||
| Smoking History | ||||||
| No history | Ref | 0.01 | Ref | 0.33 | Ref | 0.38 |
| Current or former smoker | 0.36 (0.16–0.8) | 1.35 (0.74–2.44) | 0.65 (0.25–1.70) | |||
| History of CVD | ||||||
| Yes | 0.80 (0.42–1.53) | 3.46 (1.87, 6.41) | 1.43 (0.58–3.52) | |||
| No | Ref | 0.5 | Ref | < 0.0001 | Ref | 0.44 |
| History of Diabetes | ||||||
| Yes | 0.54 (0.27–1.10) | 2.49 (1.34–4.65) | 1.07 (0.33–3.46) | |||
| No | Ref | 0.09 | Ref | 0.004 | Ref | 0.91 |
| BMI | ||||||
| Normal/Overweight | Ref | 0.35 | Ref | 0.38 | Ref | 0.25 |
| Obese | 1.39 (0.70–2.76) | 1.29 (0.73–2.26) | 1.87 (0.65–5.39) | |||
| Psychosocial Factors | ||||||
| Worry/Bother about personal CRC risk | 2.45 (1.53–3.92) | 0.0002 | 0.89 (0.66–1.19) | 0.43 | 0.93 (0.57–1.54) | 0.79 |
| Worry/Bother personal risk of non-CRC cancers | 2.36 (1.46–3.82) | 0.0005 | 1.06 (0.78–1.44) | 0.72 | 1.07 (0.62–1.87) | 0.80 |
| Concern about CRC risk for family members | ||||||
| High concern | Ref | 0.87 | Ref | 0.12 | Ref | 0.20 |
| Low/no concern | 1.06 (0.56–2.00) | 1.55 (0.89–2.69) | 0.55 (0.22–1.36) | |||
| Distress | ||||||
| Low/no distress | Ref | 0.88 | Ref | 0.86 | Ref | 0.16 |
| Mid/high distress | 1.06 (0.52–2.15) | 0.95 (0.52–1.73) | 2.49 (0.69–8.97) | |||
Abbreviations ASA : daily aspirin use, BMI: Body Mass Index, CI: confidence interval, CRC: colorectal cancer, CVD: cardiovascular disease, GED: general education diploma, NHW: non-Hispanic White, NSAID: non-steroidal anti-inflammatory
Notes: 1-Only CRC survivors currently not using ASA or any NSAIDs were included in this analysis (n = 144)